Luis Velez, MD
Nephrology · San Antonio, TXNPI 1053328336
Payments from drug & device makers
Across 930 payments — averaging $543.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$331K
- Travere Therapeutics, Inc.$160K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$8K
- Amgen$1K
- OPKO Pharmaceuticals, LLC$639
- AstraZeneca$555
- plus $4K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 464 | $331,297 |
| Travere Therapeutics, Inc. | 260 | $159,641 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $8,292 |
| Amgen(2 entities) | 40 | $1,031 |
| OPKO Pharmaceuticals, LLC | 20 | $639 |
| AstraZeneca(2 entities) | 18 | $555 |
| Aurinia Pharma U.S., Inc. | 15 | $510 |
| Mallinckrodt Hospital Products Inc. | 23 | $487 |
| Calliditas Therapeutics US Inc. | 11 | $318 |
| Akebia Therapeutics Inc | 8 | $270 |
| Bayer | 6 | $250 |
| Vifor Pharma, Inc. | 10 | $224 |
| Mallinckrodt Enterprises LLC | 7 | $216 |
| Novo Nordisk | 3 | $164 |
| Corcept Therapeutics | 2 | $132 |
| Bard Peripheral Vascular, Inc. | 1 | $128 |
| Novartis | 4 | $121 |
| Cormedix Inc. | 2 | $115 |
| Ardelyx, Inc. | 4 | $94 |
| Fresenius USA Marketing, Inc. | 4 | $82 |
| GSK | 4 | $74 |
| Nxstage Medical, Inc. | 2 | $69 |
| Lilly USA, LLC | 3 | $68 |
| ANI Pharmaceuticals, Inc. | 3 | $62 |
| Edwards Lifesciences | 3 | $46 |
| Johnson & Johnson | 1 | $35 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| AbbVie | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$505,050 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in San Antonio
- Pablo PergolaSan Antonio$14.2M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Wesley CalhounSan Antonio$3.5M
- Shweta BansalSan Antonio$1.7M
- Robert SzewcSan Antonio$1.5M
- Rashid SharafSan Antonio$661K
- Varshasb BroumandSan Antonio$538K
- Steven GougeSan Antonio$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.